Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Jade Biosciences, Inc. NASDAQ:JBIO | $1.03B | $16.14 | Not rated | -7.4 | +24.32% |
Crescent Biopharma, Inc. NASDAQ:CBIO | $525.59M | $14.15 | Not rated | -3.3 | -4.83% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | $14.30 | Not rated | -1.1 | -19.34% |
AN2 Therapeutics, Inc. NASDAQ:ANTX | $172.64M | $4.55 | Not rated | -4.9 | +358.33% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.17% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $37.49M | $1.58 | Not rated | -2.5 | -65.57% |
Pelthos Therapeutics Inc. AMEX:PTHS | $29.25M | $7.44 | Not rated | -0.7 | -44.89% |
Continue the stock analysis
Jump to another research area for this company.